OBJECTIVE： To systematically review the efficacy and safety of Moxifloxacin （MFX） in the treatment of acute exacerbation of chronic bronchitis （AECB）， and provide evidence-based reference for Tational use of MFX. METHODS： Retrieved from PubMed， EMBase， Cochrane Library， Medline， CBM， CJFD， VIP and Wanfang Database， the relevant conference proceedings and grey literature were also hand-searched， randomized controlled trials （RCT） about MFX （test group） versus other antibiotics （control group） in the treatment of AECB were collected. Meta-analysis was performed by using Rev Man 5.2 software with ITT analysis and PP analysis after literature selection， data extraction and quality evaluation. RESULTS： Totally 14 RCTs were included， involving 6 058 patients. Results of PP analysis showed， the clinical effective rate in test group was similar to that of control group [RR＝1.02，95％CI（1.00，1.04），P＝0.06]， while bacteria clearance rate was significantly higher than control group [RR＝1.07，95％CI（1.04，1.11），P＜0.001]. Results of ITT analysis showed， the clinical effective rate in test group was significantly higher than control group [RR＝1.03， 95％CI（1.00，1.06），P＝0.03]， while there was no significant difference in the bacteria clearance rate [RR＝1.02，95％CI（0.92，1.12），P＝0.73] and the incidence of adverse reactions [RR＝0.97，95％CI（0.87，1.08），P＝0.52] between 2 groups. CONCLUSIONS： The efficacy of MFX is not inferior to other antibiotics in the treatment of AECB， safety is similar to other antibiotics.